LPL Financial
INSY

LPL Financial’s Insys Therapeutics, Inc. INSY Stock Holding History

LPL Financial’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10,212
Closed -$62K – 3324
2018
Q1 		$62K Buy
+10,212
New +$84.3K ﹤0.01% 3112
2017
Q3 		– Sell
-13,396
Closed -$169K – 2969
2017
Q2 		$169K Buy
+13,396
New +$159K ﹤0.01% 2629

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

LPL Financial's INSY Position: Q2 2018 in Review

LPL Financial sold out of Insys Therapeutics, Inc. (INSY) in Q2 2018, closing a stake of 10,212 shares — an estimated $62K sold.

LPL Financial first reported a position in INSY in Q2 2017 and held it in 2 quarters. The position peaked at $169K in Q2 2017. 103 funds tracked by Wall St. Rank hold INSY as of Q2 2018.

  • LPL Financial reported no remaining Insys Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • LPL Financial sold 10,212 Insys Therapeutics, Inc. shares in Q2 2018, an estimated $62K.
  • LPL Financial first reported a position in Insys Therapeutics, Inc. in Q2 2017 and held it in 2 quarters.
  • LPL Financial's Insys Therapeutics, Inc. position peaked at $169K in Q2 2017.
  • 103 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2018.

Based on LPL Financial's 13F filing for Q2 2018, filed 14 Aug 2018.